根据名称进行药物检索

Irinotecan Intravenous 与 Oxcarbazepine Oral Suspension

Irinotecan Intravenous 与 Oxcarbazepine Oral Suspension互相作用以及同时服用的可能性。

检测结果:

Irinotecan Intravenous <> Oxcarbazepine Oral Suspension

现实性: 06.08.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

奥卡西平可以降低血液水平的替康. 在某些情况下，这可能使药物不太有效地治疗癌症。谈谈你的医生如果你有任何疑问或关切的问题。你的医生可以规定替代品，不进行互动，或者可能需要一剂量的调整或更频繁的监测通过你的医生到安全地使用这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

监视器：共同给予与的诱导剂的CYP450 3A4同工酶可以减少等离子浓度的替康和药理学活性代谢物，SN-38。康是部分地代谢通过CYP450 3A4，诱导这一进程的结果，在更少的药物可用于等离子用于转换到SN-38通过carboxylesterases. 相互作用已经报告了与圣约翰草和酶诱导抗惊厥药的卡马西平，苯巴比妥，并苯妥英。一个大约减少40%SN-38系统暴露(AUC)报告了存在的圣约翰草和大于60%减少已经报告了存在的酶诱导的抗惊厥药。然而，所有这些制剂被称为是有力的诱导剂的CYP450 3A4以及其他酶途径(例如，UDP中转移，或UGT;carboxylesterases)和药物转运(例如，多特异性有机的阴离子运输，或MRP2；P-糖蛋白质)，可参与清除康和/或SN-38。的程度，如果有，这种药可能与较有力CYP450 3A4的诱导剂是未知的。

管理：抗肿瘤的活性的替康可能减少治疗的患者CYP450 3A4诱导物。药物响应药，应该监测更密切地时CYP450 3A4诱加入或撤出疗法，药的剂量进行调整是必要的。

来源

Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ "Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies." Clin Cancer Res 5 (1999): 1325-30
"Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.
Radomski KM, Gajjar AJ, Kirstein MN, et al "Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme." Pharmacotherapy 20 (2000): 353
Kuhn JG "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40
Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K "Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer." Int J Clin Oncol 9 (2004): 206-9
Friedman HS, Petros WP, Friedman AH, et al "Irinotecan therapy in adults with recurrent or progressive malignant glioma." J Clin Oncol 17 (1999): 1516-25
Santos A, Zanetta S, Cresteil T, et al "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans." Clin Cancer Res 6 (2000): 2012-20
Murry DJ, Cherrick I, Salama V, et al. "Influence of phenytoin on the disposition of irinotecan: a case report." J Pediatr Hematol Oncol 24 (2002): 130-3
Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A "Effects of St. John's Wort on Irinotecan Metabolism." J Natl Cancer Inst 94 (2002): 1247-9
Di YM, Li CG, Xue CC, Zhou SF "Clinical drugs that interact with St. John's wort and implication in drug development." Curr Pharm Des 14 (2008): 1723-42
Zamboni WC, Gajjar AJ, Heideman RL, et al "Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma." Clin Cancer Res 4 (1998): 783-9
Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A "Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603." ([2002 Apr]):
Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9
"Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.
Innocenti F, Undevia SD, Ramirez J, et al. "A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital." Clin Pharmacol Ther 76 (2004): 490-502